At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Location: United Kingdom, England, Kenilworth
Employees: 11-50
Total raised: $78M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.07.2015 | Series C | $55M | - |
| 16.12.2009 | Series A | $23M | - |
Mentions in press and media 8
| Date | Title | Description |
| 10.06.2016 | Healthcare Company Merck to Buy Afferent Pharmaceuticals For up to $1.25 Billion | Global health care company Merck (NYSE:MRK), is to acquire* Afferent Pharmaceuticals, a San Mateo, CA-based pharmaceutical company that develops therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed,... |
| 10.06.2016 | Merck bags PhIII-bound Afferent Pharma in $1.25B deal | Last summer, the low-profile biotech Afferent Pharmaceuticals looked like it was prepping a jump into the IPO queue, raising a $55 million C round from a set of crossover investors. The market went into a deep chill, the IPO never materiali... |
| 09.07.2015 | Afferent Pharmaceuticals Grabs $55M | SAN MATEO, CA, Afferent Pharmaceuticals, a leader in the development of novel small molecule drugs for the treatment of neurogenic respiratory, urologic and pain disorders, today announced the completion of a $55 million Series C round. ... |
| 08.07.2015 | Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing | |
| 08.07.2015 | Afferent Pharmaceuticals Completes $55m Series C Financing | Afferent Pharmaceuticals, a San Mateo, CA-based developer of drugs for the treatment of a range of debilitating neurogenic disorders, completed a $55m Series C financing. The round was led by Fidelity Management & Research Company, with... |
| 15.01.2010 | Venture Investors Spread Holiday Cheer to Mass. Startups in December: Companies Wrap Up $224 Million in Funding | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Santa was good to the Massachusetts high-tech economy in December. Very good. Roughly $224 million poured into the state’s startups in 36 equity deals, representing 20 percent... |
| 16.12.2009 | Afferent Pharmaceuticals Closes $23M Series A Financing Round | Afferent Pharmaceuticals, a Palo Alto, CA-based company focused on developing compounds that treat chronic pain, closed a $23m Series A financing round. The round was led by Third Rock Ventures and Pappas Ventures, with participation from D... |
| 19.03.2009 | Merck’s Creationist-Turned-Genomicist, Pfizer’s VC Leader Scouts the Northwest, Zymo Nabs $20M, & More Seattle-Area Life Sciences News | Share Share on Facebook Share on Twitter LinkedIn Email Reprints This was a busy week in Xconomy’s life sciences department with lots of story ideas to chase at Invest Northwest, a fascinating life story of Merck’s Eric Schadt, and the usua... |